A Double Strike Against Tumor Resistance

1. D’Accardo, C. et al. Cancer cell targeting by CAR-T cells: A matter of stemness. Front. Mol. Med. 2, (2022).

2. Zhang, K. et al. IL-24 improves efficacy of CAR-T cell therapy by targeting stemness of tumor cells. Br. J. Cancer 130, 1337–1347 (2024).

3. Chen, T., Wang, M., Chen, Y. & Liu, Y. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int. 24, 133 (2024).

4. Guzman, G., Reed, M. R., Bielamowicz, K., Koss, B. & Rodriguez, A. CAR-T Therapies in Solid Tumors: Opportunities and Challenges. Curr. Oncol. Rep. 25, 479–489 (2023).

5. Prager, B. C., Xie, Q., Bao, S. & Rich, J. N. Cancer Stem Cells: The Architects of the Tumor Ecosystem. Cell Stem Cell 24, 41–53 (2019).

6. Modi, J. et al. Insights into the Mechanisms of Action of MDA-7/IL-24: A Ubiquitous Cancer-Suppressing Protein. Int. J. Mol. Sci. 23, 72 (2022).

7. Targeting breast cancer‐initiating/stem cells with melanoma differentiation‐associated gene‐7/interleukin‐24 - Bhutia - 2013 - International Journal of Cancer - Wiley Online Library. https://onlinelibrary.wiley.com/doi/10.1002/ijc.28289.

8. Craddock, J. A. et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. Hagerstown Md 1997 33, 780–788 (2010).

9. Fultang, L. et al. Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood 136, 1155–1160 (2020).

10. McKenzie, T. et al. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu–overexpressing breast cancer cells. Surgery 136, 437–442 (2004).